Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

NCT03648489 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Ovarian Neoplasms
Ovarian Carcinosarcoma
Ovarian Serous Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Fallopian Tube Cancer
Fallopian Tube Neoplasms
Primary Peritoneal Carcinoma
Primary Peritoneal Serous Adenocarcinoma

Interventions

DRUG: Paclitaxel
DRUG: TAK228

Sponsor

Imperial College London

Collaborators

[object Object]
[object Object]